home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap

UBBFriend: Email This Page to Someone!
  Biotechnical requests and sources
  AnaSpec Introduces New PKD1 & PKD2 Antibodies

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   AnaSpec Introduces New PKD1 & PKD2 Antibodies
posted 10-21-2008 11:36 PM     Click Here to See the Profile for anaspec   Click Here to Email anaspec     Edit/Delete Message Reply w/Quote
San Jose, CA – October 21, 2008

Protein kinase D (PKD), a serine/threonine kinase originally described as a novel PKC family member and termed PKCm (1), belongs to the calcium calmodulin superfamily of kinases (2-3). Three mammalian isoforms have so far been described - PKD1/PKCm, PKD2 and PKD3/PKCn; these isoforms show a high degree of homology, especially in their catalytic domain (4-5). PKDs are major targets for tumor promoting phorbol esters; they are activated via G protein-coupled receptors (GPCRs) and their activation is also dependent on PKC activation (5). PKDs have been implicated in numerous cellular functions, including signal transduction as well as cell survival, migration, differentiation, and proliferation (4-6). They are important regulators of secretory transport at the trans-golgi network (7). Of the three isoforms, PKD1 is the best characterized. It is involved in the regulation of Golgi function, cell proliferation and apoptosis (8) and it mediates oxidative stress signaling regulating cellular detoxification and survival (9). PKD2 has been found to phosphorylate histone H1 more efficiently than aldolase in vitro (10).

AnaSpec is pleased to announce the release of isoform specific PKD1 and PKD2 antibodies. These antibodies were raised using sequences from the C-terminus of PKD1 and PKD2. Anti-PKD1 only recognizes PKD1 and not PKD2 and PKD3. Anti-PKD2 only recognizes PKD2 and not PKD1 or PKD3.

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

For more information visit www.anaspec.com

1. Johannes, FJ. et al. J. Biol. Chem. 269, 6140 (1994).
2. Manning, G. et al. Science 298, 1912 (2002).
3. Van Lint, J. et al. Trends Cell Biol. 12, 193 (2002).
4. Waldron, RT. et al. J. Biol. Chem. 276, 32606 (2001).
5. Auer, A. et al. Mol. Bio. Cell. 16, 4375 (2005).
6. Rozengurt, E. et al. J. Biol. Chem. 208, 13205 (2005).
7. Yeaman, C. et al. Nature Cell Biol. 6, 106 (2004).
8. Rykx, A. et al. FEBS Lett. 546, 81 (2003).
9. Döppler, H. & P. Storz, et al. J. Biol. Chem. 282, 31873 (2007).
10. Sturany, S. et al. J. Biol. Chem. 276, 3310 (2001).



All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2017

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.